Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 7, 2004, Pages 283-289

  Bekaii Saab, Tanios S ^a,b,c   Perloff, Michael D ^a   Weemhoff, James L ^a   Greenblatt, David J ^a   von Moltke, Lisa L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

CYP3A; P glycoprotein; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; GLYCOPROTEIN P; NORTAMOXIFEN; RHODAMINE 123; TAMOXIFEN; TRIAZOLAM; VERAPAMIL;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; IN VITRO STUDY; LIVER MICROSOME; PROTEIN TRANSPORT;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; TAMOXIFEN;

EID: 6444239304     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.411     Document Type: Article

References (44)

1. Buckley MMT, Goa KL. Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic uses. Drugs 1989; 37: 451-490.
2. Plowman PN. Tamoxifen as adjuvant therapy in breast cancer. Drugs 1993; 46: 819-833.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 990: 1371-1388.
4. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
5. Williams ML, Lennard MS, Martin LJ, Ticker GT. Inter-individual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis 1994; 15: 2733-2738.
6. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002; 30: 869-874.
7. Mani C, Gelboin HV, Park SS, Peace R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hdroxylation. Drug Metab Dispos 1993; 21: 645-656.
8. Coller JK, Krebsfaenger N, Klein K, et al. Large inter-individual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br J Clin Pharmacol 2004; 57: 105-111.
9. Coller JK, Krebsfaenger N, Klein K, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54:, 157-167.
10. Coller JK. Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. Clin Exp Pharmacol Physiol 2003; 30: 845-848.
11. Kim SY, Suzuki N, Santosh Laxmi YR, Rieger R, Shibutani S. Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol 2003; 16: 1138-1144.
12. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF. Bioactivities, estrogen receptor interactions, and plasminogen activator inducing activities of tamoxifen and 4-hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984; 44: 112-119.
13. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocrinol 1977; 75: 305-316.
14. Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 1993; 13: 88-109.
15. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-170.
16. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 363-382.
17. Matheny CJ, Lamb MW, Brouwer KL, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-796.
18. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003; 35: 417-454.
19. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003; 55: 53-81.
20. Rao US, Fine R, Scarborough G. Antiestrogens and steroid hormones: Substrates of the human P-glycoprotein. Biochem Pharmacol 1994; 48: 287-292.
21. Callaghan R, Higgins CF. Interaction of tamoxifen with multidrug resistance P-glycoprotein. Br J Cancer 1995; 71: 294-299.
22. Zalcberg JR, Hu XF, Ching M, et al. Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines. Cancer Chemother Pharmacol 1993; 33: 123-129.
23. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6: 610-617.
24. Wang EJ, Casciano CN, Clement RP, Johnson WW. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 2000; 28: 522-528.
25. Guengerich FP. Mechanism-based inactivation of human liver cytochrome P450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3: 363-371.
26. Baumhakel M, Kasel D, Rao-Scymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001; 39: 517-528.
27. Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32: 863-878.
28. Quaroni A, Hochman J. Development of intestinal cell culture models for drug transport and metabolism studies. Adv Drug Deliv Rev 1996; 22: 3-52.
29. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models. J Clin Pharmacol 2001; 41: 1149-1179.
30. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 2003; 4: 423-459.
31. Störmer E, Perloff MD, von Moltke LL, Greenblatt DJ. Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos 2001; 29: 954-956.
32. von Moltke LL, Greenblatt DJ, Duan SX, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-379.
33. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111.
34. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
35. von Moltke LL, Weemhoff JL, Perloff MD, et al. Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos 2002; 23: 361-367.
36. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: Correlation with reduced levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991; 83: 1477-1482.
37. Osborne CK, Wiebe V, McGuire WL, Ciocca DR, DeGregorio M. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 1992; 10: 304-310.
38. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
39. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 1996; 22: 67-84.
40. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160-1167.
41. 2+ channel blocker drugs on the cellular accumulation of the anticancer drug daunarubicin: P-glycoprotein modulation. J Pharmacol Exp Ther 2000; 295: 1276-1283.
42. Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specifities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-134.
43. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Del Rev 1996; 20: 99-112.
44. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-318.